Aldeyra shows FDA-rejected reproxalap improves eye discomfort in new phase 3 study.

MLA

Masson, Gabrielle. “Aldeyra Shows FDA-Rejected Reproxalap Improves Eye Discomfort in New Phase 3 Study.” FierceBiotech, Aug. 2024, p. N.PAG. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=178936097&authtype=sso&custid=ns315887.

APA

Masson, G. (2024). Aldeyra shows FDA-rejected reproxalap improves eye discomfort in new phase 3 study. FierceBiotech, N.PAG.

Chicago

Masson, Gabrielle. 2024. “Aldeyra Shows FDA-Rejected Reproxalap Improves Eye Discomfort in New Phase 3 Study.” FierceBiotech, August, N.PAG. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=178936097&authtype=sso&custid=ns315887.